ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0329

Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
Abstract Number: 1261

Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Abstract Number: 0234

Scouting Reports as a Social Constructivist Teaching Tool in RheumMadness
Abstract Number: 0665

Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging
Abstract Number: 0896

Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
Abstract Number: 1020

Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
Abstract Number: PP06

Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
Abstract Number: 0495

Seasonal Variation in the Incidence of GCA in the UK and Ireland
Abstract Number: 1193

Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample
Abstract Number: 1323

Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
Abstract Number: 1514

Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
Abstract Number: 0615

Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
Abstract Number: 0168

Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)
Abstract Number: 0209

Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Abstract Number: 2192

Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].